Clinical implications of very low on-treatment platelet reactivity in patients treated with thienopyridine: the POBA study (predictor of bleedings with antiplatelet drugs).
Thomas Cuisset,Charlotte Grosdidier,Charlotte Grosdidier,Anderson Diendonné Loundou,Jacques Quilici,Jacques Quilici,Marie Loosveld,Marie Loosveld,Laurence Camoin,Mathieu Pankert,Shirley Beguin,Marc Lambert,Marc Lambert,Pierre-Emmanuel Morange,Pierre-Emmanuel Morange,Jean-Louis Bonnet,Jean-Louis Bonnet,Marie-Christine Alessi,Marie-Christine Alessi +18 more
Reads0
Chats0
TLDR
VLTPR (PRI VASP ≤10%) was identified as the strongest predictor of bleeding complications in patients treated with thienopyridines, and could be useful for tailored therapy and bleeding prevention.Abstract:
Objectives: This study was designed to define the hyperresponse to thienopyridine (very low on-treatment platelet reactivity [VLTPR]) as the most predictive threshold value of platelet reactivity i...read more
Citations
More filters
Journal ArticleDOI
Long-Term Use of Ticagrelor in Patients with Prior Myocardial Infarction
Marc P. Bonaca,Deepak L. Bhatt,Marc Cohen,Philippe Gabriel Steg,Robert F. Storey,Eva C. Jensen,Giulia Magnani,Sameer Bansilal,M. Polly Fish,KyungAh Im,Olof Bengtsson,Ton Oude Ophuis,Andrzej Budaj,Pierre Theroux,Mikhail Ruda,Christian W. Hamm,Shinya Goto,Jindrich Spinar,Jose C. Nicolau,Róbert Gábor Kiss,Sabina A. Murphy,Stephen D. Wiviott,Peter Held,Eugene Braunwald,Marc S. Sabatine +24 more
TL;DR: In patients with a myocardial infarction more than 1 year previously, treatment with ticagrelor significantly reduced the risk of cardiovascular death, my Cardiac Infarction, or stroke and increased therisk of major bleeding.
Journal ArticleDOI
General Cardiology AbstractsPredictors of major bleeding in acute coronary syndromes: the global registry of acute coronary events (GRACE)
TL;DR: In routine clinical practice, major bleeding is a relatively frequent non-cardiac complication of contemporary therapy for ACS and it is associated with a poor hospital prognosis and it was significantly associated with an increased risk of hospital death.
Journal ArticleDOI
Incidence, Predictors, and Impact of Post-Discharge Bleeding After Percutaneous Coronary Intervention
Philippe Généreux,Gennaro Giustino,Bernhard Witzenbichler,Giora Weisz,Thomas Stuckey,Michael J. Rinaldi,Franz-Josef Neumann,D. Christopher Metzger,Timothy D. Henry,David A. Cox,Peter L. Duffy,Ernest L. Mazzaferri,Mayank Yadav,Dominic P. Francese,Tullio Palmerini,Ajay J. Kirtane,Claire Litherland,Roxana Mehran,Gregg W. Stone +18 more
TL;DR: After successful PCI with DES in an unrestricted patient population, PDB is not uncommon and has a strong relationship with subsequent all-cause mortality, greater that that associated with PDMI.
Journal ArticleDOI
Interventional Cardiology AbstractsDouble-blind study of the safety of clopidogrel with and without a loading dose in combination with aspirin compared with ticlopidine in combination with aspirin after coronary stenting: the Clopidogrel Aspirin Stent International Cooperative Study (CLASSICS)
TL;DR: Primary end point data are consistent with the hypothesis that clopidogrel and ticlopidine have comparable efficacy with regard to cardiac events after successful stenting, and the 300-mg loading dose was well tolerated, notably with no increased risk of bleeding.
References
More filters
Journal ArticleDOI
Prasugrel versus Clopidogrel in Patients with Acute Coronary Syndromes
Stephen D. Wiviott,Eugene Braunwald,Carolyn H. McCabe,Gilles Montalescot,Witold Rużyłło,Shmuel Gottlieb,Franz Joseph Neumann,Diego Ardissino,Stefano De Servi,Sabina A. Murphy,Jeffrey S. Riesmeyer,Govinda Weerakkody,C. Michael Gibson,Elliott M. Antman +13 more
TL;DR: In patients with acute coronary syndromes with scheduled percutaneous coronary intervention, prasugrel therapy was associated with significantly reduced rates of ischemic events, including stent thrombosis, but with an increased risk of major bleeding, including fatal bleeding.
Journal ArticleDOI
Effects of clopidogrel in addition to aspirin in patients with acute coronary syndromes without ST-segment elevation.
Salim Yusuf,Zhao F,Shamir R. Mehta,Susan Chrolavicius,Gianni Tognoni,K K Fox,Clopidogrel in Unstable Angina to Prevent Recurrent Events Trial Investigators +6 more
TL;DR: The antiplatelet agent clopidogrel has beneficial effects in patients with acute coronary syndromes without ST-segment elevation, however, the risk of major bleeding is increased among patients treated with clopIDogrel.
Journal ArticleDOI
Ticagrelor versus Clopidogrel in Patients with Acute Coronary Syndromes
Lars Wallentin,Richard C. Becker,Andrzej Budaj,Christopher P. Cannon,Håkan Emanuelsson,Claes Held,Jay Horrow,Steen Husted,Stefan James,Hugo A. Katus,Kenneth W. Mahaffey,Benjamin M. Scirica,Allan M. Skene,Philippe Gabriel Steg,Robert F. Storey,Robert A. Harrington +15 more
TL;DR: In patients who have an acute coronary syndrome with or without ST-segment elevation, treatment with ticagrelor as compared with clopidogrel significantly reduced the rate of death from vascular causes, myocardial infarction, or stroke without an increase in the rates of overall major bleeding but with an increase of non-procedure-related bleeding.
Journal ArticleDOI
Standardized Bleeding Definitions for Cardiovascular Clinical Trials A Consensus Report From the Bleeding Academic Research Consortium
Roxana Mehran,Sunil V. Rao,Deepak L. Bhatt,C. Michael Gibson,Adriano Caixeta,John W. Eikelboom,Sanjay Kaul,Stephen D. Wiviott,Venu Menon,Eugenia Nikolsky,Victor L. Serebruany,Marco Valgimigli,Pascal Vranckx,David P. Taggart,Joseph F. Sabik,Donald E. Cutlip,Mitchell W. Krucoff,E. Magnus Ohman,Philippe Gabriel Steg,Harvey D. White +19 more
TL;DR: Bleeding complications have been associated with an increased risk of subsequent adverse outcomes, including MI, stroke, stent thrombosis, and death, in patients with ACS and in those undergoing percutaneous coronary intervention (PCI) as well as in the long-term antithrombotic setting.
Journal ArticleDOI
Effects of pretreatment with clopidogrel and aspirin followed by long-term therapy in patients undergoing percutaneous coronary intervention: the PCI-CURE study.
Shamir R. Mehta,Salim Yusuf,Ron J.G. Peters,Michel E. Bertrand,Basil S. Lewis,Madhu K. Natarajan,Klas Malmberg,Hans-Jürgen Rupprecht,Feng Zhao,Susan Chrolavicius,Ingrid Copland,Keith A.A. Fox +11 more
TL;DR: In patients with acute coronary syndrome receiving aspirin, a strategy of clopidogrel pretreatment followed by long-term therapy is beneficial in reducing major cardiovascular events, compared with placebo.
Related Papers (5)
Prasugrel versus Clopidogrel in Patients with Acute Coronary Syndromes
Ticagrelor versus Clopidogrel in Patients with Acute Coronary Syndromes
Bedside monitoring to adjust antiplatelet therapy for coronary stenting.
Jean-Philippe Collet,Thomas Cuisset,Grégoire Rangé,Guillaume Cayla,Simon Elhadad,Christophe Pouillot,Patrick Henry,Pascal Motreff,Didier Carrié,Ziad Boueri,Loic Belle,Eric Van Belle,Hélène Rousseau,Pierre Aubry,Jacques Monsegu,Pierre Sabouret,Jérémie Abtan,Mathieu Kerneis,Christophe Saint-Etienne,Olivier Barthelemy,Farzin Beygui,Johanne Silvain,Eric Vicaut,Gilles Montalescot +23 more
Consensus and Update on the Definition of On-Treatment Platelet Reactivity to Adenosine Diphosphate Associated With Ischemia and Bleeding
Udaya S. Tantry,Laurent Bonello,Daniel Aradi,Matthew J. Price,Young-Hoon Jeong,Dominick J. Angiolillo,Gregg W. Stone,Nicholas Curzen,Tobias Geisler,Jurriën M. ten Berg,Ajay J. Kirtane,Jolanta M. Siller-Matula,Elisabeth Mahla,Richard C. Becker,Deepak L. Bhatt,Ron Waksman,Sunil V. Rao,Dimitrios Alexopoulos,Rossella Marcucci,Jean-Luc Reny,Dietmar Trenk,Dirk Sibbing,Paul A. Gurbel +22 more
Standard- vs high-dose clopidogrel based on platelet function testing after percutaneous coronary intervention: the GRAVITAS randomized trial.
Matthew J. Price,Peter B. Berger,Paul S. Teirstein,Jean-François Tanguay,Dominick J. Angiolillo,Douglas Spriggs,Sanjeev Puri,Mark Robbins,Kirk N. Garratt,Olivier F. Bertrand,Michael E. Stillabower,Joseph Aragon,David E. Kandzari,Curtiss T. Stinis,Michael S. Lee,Steven V. Manoukian,Christopher P. Cannon,Nicholas J. Schork,Eric J. Topol +18 more